Ahead Of The Mix: Symphogen Leads The Way To Antibody Combinations
This article was originally published in Start Up
Executive Summary
The concept of multiple antibodies in one mixture to treat disease, once solely the provenance of serum-derived polyclonal therapies, is enticing a new wave of developers. With a technological head start and a vault full of private backing, Danish firm Symphogen is the field’s pioneer – and hopes to avoid the arrows.
You may also be interested in...
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.